Skip to content

Eli Lilly LLY Long-Term Debt

Long-Term Debt at other companies

Pfizer logo
PfizerPFE
$60.57B+5.1%
Amgen logo
AmgenAMGN
$51.89B-3.9%
McKesson logo
McKessonMCK
$6.6B+17.9%
Lexicon Pharmaceuticals logo
Lexicon PharmaceuticalsLXRX
$49.68M-15.3%
Cencora logo
CencoraCOR
$12.18B+71.9%
Cardinal Health logo
Cardinal HealthCAH

Other financials

Income statement

See full
Revenue$19.8B+55.5%
Gross profit$16.2B+54.4%
Net income$7.4B+168%
EPS (diluted)$8.26+170%

Balance sheet

See full
Cash & equivalents$5.3B+70.8%
Total debt$43.4B+12.6%
Total equity$31.2B+97.9%
Total assets$116.58B+30.4%

Cash flow

See full
Operating cash flow$5.3B+220%
CapEx$2.3B+54.0%
Free cash flow$3.0B+1,828%

Valuation

See full
Market cap$1.09T+56.4%
Enterprise value$1.12T+53.8%
P/E42.9×-7.3×
P/S15×+2.0×

Profitability

See full
Gross margin82.8%+1.1pp
Net margin35%+12.3pp
FCF margin16.4%+8.7pp

Returns & leverage

See full
Return on equity107.6%+29.9pp
Debt / equity1.4×-1.1×
Current ratio1.5×+0.1×

Where this comes from

Reported directly by Eli Lilly in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtNoncurrent.

The official record: Eli Lilly’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Eli Lilly's long-term debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Eli Lilly's long-term debt?
Eli Lilly (LLY) reported long-term debt of $39.37B in Q1 2026.
How has Eli Lilly's long-term debt changed year-over-year?
Eli Lilly's long-term debt increased by 14.1% year-over-year, from $34.5B to $39.37B.
What is the long-term trend for Eli Lilly's long-term debt?
Over 5 years (2020 to 2025), Eli Lilly's long-term debt has grown at a 19.8% compound annual growth rate (CAGR), from $16.59B to $40.87B.
What does long-term debt mean?
Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.